Oncoshot, an AI-driven platform that facilitates data-driven cancer clinical trials, has announced a partnership with the well-known contract research organization (CRO) Novotech to enhance clinical trial management success.
This partnership is expected to grant exchange and insights into real-time population data between both organisations and their affiliated leading cancer research centres.
Typically, CROs provide clinical trial services for pharmaceutical, biotechnology, and medical device institutes.
Novotech will leverage the Oncoshot platform to understand matching populations across key clinical trial markets in the APAC region. While Oncoshot will provide a secure insights-sharing framework where Novotech can conduct feasibility studies with data-ready trial sites aggregated on the platform. This will facilitate ease of engagement and efficiency in starting and conducting clinical trials.
With the enhanced capabilities, Novotech will now be able to access national-level genomic screening partners such as Omico, and will be better equipped to identify sites, assess their feasibility, and identify patient geographies.
It will also be able to engage with leading cancer hospitals for feasibility and continuously refreshed data to support screening and enrolment throughout the duration of clinical trials.
